Vistagen's PALISADE-3 Phase 3 study of fasedienol fails primary endpoint in social anxiety disorder

Vistagen Therapeutics, Inc.

LS mean change from baseline on SUDS score: fasedienol 13.6 (SE 1.54) vs placebo 14.0 (SE 1.51); no statistical significance.
Secondary endpoints also showed no treatment difference between fasedienol and placebo.
Favorable safety data consistent with prior trials; no new safety signals.
Phase 3 failure likely halts development path for intranasal fasedienol in acute social anxiety.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.